+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma

Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma

Pediatric Hematology and Oncology 35(4): 257-267

Craniospinal irradiation (CSI) often results in endocrine deficiencies in children with medulloblastoma due to irradiation of the hypothalamic-pituitary axis (HPA) or the thyroid gland. CSI with Proton radiation therapy (PRT) has the potential to decrease the risk of hypothyroidism by reduction in radiation dose to these organs. This study compares the risk for hypothyroidism in patients with medulloblastoma treated with Photon radiation therapy (XRT) or PRT. The records of patients with medulloblastoma diagnosed at a single institution between 1997 and 2014 who received CSI were, retrospectively, reviewed. Ninety-five patients (54 XRT and 41 PRT) who had baseline and yearly follow-up thyroid studies were included. We used interval censored Cox regression to calculate hazard ratios of developing any, primary, and central hypothyroidism. With a median time to last thyroid studies post radiation of 3.8 years in PRT and 9.6 years in XRT, 33/95 (34.7%) patients developed hypothyroidism (median time to hypothyroidism: 2.6 years). Hypothyroidism developed in 25/54 (46.3%) who received XRT vs. 8/41 (19%) in the PRT group (HR =1.85, p = .14). Primary hypothyroidism developed in 15/95 (15.8%) patients: 12/54 (22.2%) after XRT and 3/41 (7.3%) after PRT (HR =2.1, p = .27). Central hypothyroidism developed in 17/95 (18.0%) patients: 13/54 (24.0%) after XRT and 4/41 (9.8%) after PRT (HR =2.16, p = .18). The use of PRT in patients with medulloblastoma was associated with numerically lower but not significantly lower risk of hypothyroidism. Further studies including larger numbers and longer follow up must be performed to assess whether lower radiation doses achieved with PRT show statistically significant differences.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 065996556

Download citation: RISBibTeXText

PMID: 30537887

DOI: 10.1080/08880018.2018.1471111

Related references

A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. RadioTherapy and Oncology 113(1): 84-88, 2014

Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Physics in Medicine and Biology 58(4): 807-823, 2013

A review of dosimetric and toxicity modeling of proton versus photon craniospinal irradiation for pediatrics medulloblastoma. Acta Oncologica 56(8): 1031-1042, 2017

Effects of vertebral-body-sparing proton craniospinal irradiation on the spine of young pediatric patients with medulloblastoma. Advances in Radiation Oncology 2(2): 220-227, 2017

Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiation Oncology 7: 116, 2012

Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatric Blood and Cancer 65(8): E27095, 2018

Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients. International Journal of Radiation Oncology Biology Physics 98(1): 37-46, 2017

Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. International Journal of Radiation Oncology Biology Physics 86(2): 277-284, 2013

Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. International Journal of Radiation Oncology Biology Physics 69(2): 404-410, 2007

Reduced acute toxicity for adults with medulloblastoma treated with proton beam craniospinal irradiation. Strahlentherapie und Onkologie 190(1): 111-112, 2014

Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer Journal 10(6): 386-390, 2005

SU-E-T-257: Risk of Radiogenic Second Cancer after Photon and Proton Craniospinal Irradiation. Medical Physics 39(6part13): 3762-3962, 2012

Craniospinal irradiation techniques: a dosimetric comparison of proton beams with standard and advanced photon radiotherapy. International Journal of Radiation Oncology Biology Physics 81(3): 637-646, 2011

Compliance of carboplatin and etoposide therapy in the treatment of childhood medulloblastoma before and after craniospinal irradiation. Pediatric Neurosurgery 19(6): 314-315, 1993

Analysis of Robustness of a Combined Cranial Photon and MLC-based Spinal Proton Field Matching Technique for Delivery of Craniospinal Irradiation. International Journal of Radiation Oncology*biology*physics 84(3): S280-S281, 2012